Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz–Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study
Author / Organization: Mireille Mpoudi-Etame, Tamara Tovar Sanchez, Marwân-Al-Qays Bousmah, Pierrette Omgba Bassega, Justin Olinga, Eric Mimbe, Michel Foalem, Camille Chiep, Serge Edimo, Marie Varloteaux, Raphaël Pelloquin, Nadine Lamare, Sylvie Boyer, Martine Peeters, Jacques Reynes, Alexandra Calmy, Andrew Hill, Eric Delaporte, Charles Kouanfack, Ahidjo Ayouba, A Agholeng, Christelle Butel, B Granouillac, A Lacroix, Sandrine Leroy, L Serrano, C Kounfack, Nicole Vidal, P Fouda, R Mougnoutou, V Omgba, S Tchokonte Ngandé, B Ymele, L Donfack, A Kambi, C Epoupa Mpacko, M Fotso, R Moukoko, T Nké, A Akamba, S Lekelem, S Ngono, S Tongo Fotack, M Tanga, M Tsafack, A Bissek, L Ciaffi, S Lem, M Niba, N Camille, Eitel Mpoudi-Ngole, E Ebong, G Edoul Mbesse, M Tongo, P Huynh, Gwenaëlle Maradan, Marie Libérée Nishimwe, Bruno Spire, Gilles Peytavin, Mp Lê, Yazdan Yazdanpanah, A Diallo, I Fournier, A Montoyo, N Mercier, Ventizlava Petrov‐sanchez, J Jean-Rassat, Claire Rekacewicz, C Perez Casas
| File Format | PDF (Portable Document Format) |
|---|---|
| Publication Year | 2023 |
| Source Host |
HAL Open Science
(hal.science)
|
| License / Terms | Open Access / Creative Commons |
Ready for Immediate Access
Your selected document is ready for instant access with zero mandatory waiting period.